NYSE: SNNSmith & Nephew PLC Stock
$28.39-0.38 (-1.32%)
Updated Mar 19, 2025
SNN Price
$28.39
Fair Value Price
N/A
Market Cap
$12.46B
52 Week Low
$23.65
52 Week High
$31.72
P/E
30.07x
P/B
2.37x
P/S
1.86x
PEG
0.84x
Dividend Yield
2.64%
Revenue
$5.81B
Earnings
$412.00M
Gross Margin
69.6%
Operating Margin
11.07%
Profit Margin
7.1%
Debt to Equity
0.97
Operating Cash Flow
$987M
Beta
0.85
Next Earnings
May 1, 2025
Ex-Dividend
Mar 28, 2025
Next Dividend
May 28, 2025
SNN Overview
Smith & Nephew Public Limited Company is a medical technology company focused on medical devices for use in orthopaedic reconstruction and trauma, sports medicine, ENT and advanced wound management. The company offers knee and hip implants to replace diseased, damaged or worn joints; robotics-assisted enabling technologies; and trauma products to stabilize fractures and deformity correction procedures. Smith & Nephew was founded in 1856 and is headquartered in Watford, UK.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SNN's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SNN news, forecast changes, insider trades & much more!
SNN News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SNN scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNN ($28.39) is trading above its intrinsic value of $16.98, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SNN is good value based on its earnings relative to its share price (30.07x), compared to the US market average (31.13x)
P/E vs Market Valuation
SNN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more SNN due diligence checks available for Premium users.
Valuation
SNN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
30.07x
Industry
42.37x
Market
31.13x
SNN is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SNN is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SNN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.37x
Industry
3.99x
SNN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNN price to earnings growth (PEG)
For valuing profitable companies with growth potential
SNN is good value based... subscribe to Premium to read more.
PEG Value Valuation
SNN's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SNN's Earnings (EBIT) of $643.00M... subscribe to Premium to read more.
Interest Coverage Financials
SNN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.4B
Liabilities
$5.1B
Debt to equity
0.97
SNN's short-term assets ($4.42B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNN's short-term assets ($4.42B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SNN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SNN's operating cash flow ($987.00M)... subscribe to Premium to read more.
Debt Coverage Financials
SNN vs Medical Device Stocks
Smith & Nephew Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.